180 related articles for article (PubMed ID: 24439513)
1. Improvements in metabolic abnormalities among overweight schizophrenia and bipolar disorder patients.
Ventriglio A; Gentile A; Baldessarini RJ; Martone S; Vitrani G; La Marca A; Bellomo A
Eur Psychiatry; 2014 Sep; 29(7):402-7. PubMed ID: 24439513
[TBL] [Abstract][Full Text] [Related]
2. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.
Bonaccorso S; Sodhi M; Li J; Bobo WV; Chen Y; Tumuklu M; Theleritis C; Jayathilake K; Meltzer HY
Bipolar Disord; 2015 Aug; 17(5):528-35. PubMed ID: 25874530
[TBL] [Abstract][Full Text] [Related]
3. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
4. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Correll CU; Frederickson AM; Kane JM; Manu P
Schizophr Res; 2007 Jan; 89(1-3):91-100. PubMed ID: 17070017
[TBL] [Abstract][Full Text] [Related]
5. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
6. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
[TBL] [Abstract][Full Text] [Related]
7. Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic.
Chiliza B; Asmal L; Oosthuizen P; van Niekerk E; Erasmus R; Kidd M; Malhotra A; Emsley R
Eur Psychiatry; 2015 Feb; 30(2):277-83. PubMed ID: 25577186
[TBL] [Abstract][Full Text] [Related]
8. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.
Correll CU; Robinson DG; Schooler NR; Brunette MF; Mueser KT; Rosenheck RA; Marcy P; Addington J; Estroff SE; Robinson J; Penn DL; Azrin S; Goldstein A; Severe J; Heinssen R; Kane JM
JAMA Psychiatry; 2014 Dec; 71(12):1350-63. PubMed ID: 25321337
[TBL] [Abstract][Full Text] [Related]
9. Weight gain during treatment of bipolar I patients with olanzapine.
Hennen J; Perlis RH; Sachs G; Tohen M; Baldessarini RJ
J Clin Psychiatry; 2004 Dec; 65(12):1679-87. PubMed ID: 15641874
[TBL] [Abstract][Full Text] [Related]
10. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
[TBL] [Abstract][Full Text] [Related]
11. Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
Bond DJ; Kauer-Sant'Anna M; Lam RW; Yatham LN
J Affect Disord; 2010 Jul; 124(1-2):108-17. PubMed ID: 19914720
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
[TBL] [Abstract][Full Text] [Related]
13. Non-pharmacological interventions for preventing weight gain in patients with first episode schizophrenia or bipolar disorder: A systematic review.
Nyboe L; Lemcke S; Møller AV; Stubbs B
Psychiatry Res; 2019 Nov; 281():112556. PubMed ID: 31521840
[TBL] [Abstract][Full Text] [Related]
14. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
Elmslie JL; Porter RJ; Joyce PR; Hunt PJ; Shand BI; Scott RS
Aust N Z J Psychiatry; 2009 Jan; 43(1):53-60. PubMed ID: 19085528
[TBL] [Abstract][Full Text] [Related]
15. Cardiometabolic risks and omega-3 index in recent-onset bipolar I disorder.
Wulsin LR; Blom TJ; Durling M; Welge JA; DelBello MP; Adler CM; McNamara RK; Strakowski SM
Bipolar Disord; 2018 Nov; 20(7):658-665. PubMed ID: 29479787
[TBL] [Abstract][Full Text] [Related]
16. Elevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorder.
Fiedorowicz JG; Palagummi NM; Forman-Hoffman VL; Miller DD; Haynes WG
Ann Clin Psychiatry; 2008; 20(3):131-7. PubMed ID: 18633739
[TBL] [Abstract][Full Text] [Related]
17. Effects of nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan: A randomized controlled trial.
Sugawara N; Sagae T; Yasui-Furukori N; Yamazaki M; Shimoda K; Mori T; Sugai T; Matsuda H; Suzuki Y; Ozeki Y; Okamoto K; Someya T
J Psychiatr Res; 2018 Feb; 97():77-83. PubMed ID: 29220825
[TBL] [Abstract][Full Text] [Related]
18. Latent Toxoplasma gondii infection is associated with decreased serum triglyceride to high-density lipoprotein cholesterol ratio in male patients with schizophrenia.
Sagud M; Vlatkovic S; Svob Strac D; Sviben M; Zivkovic M; Vilibic M; Vuksan-Cusa B; Mihaljevic-Peles A; Pivac N
Compr Psychiatry; 2018 Apr; 82():115-120. PubMed ID: 29477703
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Moreno C; Merchán-Naranjo J; Alvarez M; Baeza I; Alda JA; Martínez-Cantarero C; Parellada M; Sánchez B; de la Serna E; Giráldez M; Arango C
Bipolar Disord; 2010 Mar; 12(2):172-84. PubMed ID: 20402710
[TBL] [Abstract][Full Text] [Related]
20. Metabolic syndrome: differences between psychiatric and internal medicine patients.
Margari F; Lozupone M; Pisani R; Pastore A; Todarello O; Zagaria G; Minerva F; Palasciano G; Palmieri V
Int J Psychiatry Med; 2013; 45(3):203-26. PubMed ID: 24066405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
